Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

GRCE

Live52w low +22.9%

Annual Quarterly

Core line items from GRCE's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: GRACE THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q2 2026 (Est.) Expected 2026-06-23	Annual 2022 2022-03-31	Q4 2021 2021-12-31	Annual 2021 2021-03-31	Q4 2020 2020-12-31
Revenue	$0.00	$0.00	$0.00	$196.00K	$81.00K
Operating Income	Not available	$-15.59M	$-11.19M	$-16.42M	$-14.12M
Net Income	Not available	$-9.82M	$-5.92M	$-19.68M	$-14.03M
EPS (Diluted)	$-0.23	$-0.27	$-0.23	Not available	Not available
Total Assets	Not available	$128.62M	$114.23M	$62.46M	$30.30M
Total Liabilities	Not available	$20.35M	$3.17M	$6.80M	$4.59M
Cash & Equivalents	Not available	$30.34M	$33.01M	$50.94M	$26.55M
Free Cash Flow OCF − CapEx	Not available	Not available	Not available	Not available	Not available
Shares Outstanding	Not available	44.29M	25.79M	Not available	Not available

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from GRCE's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +22.9%

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: GRACE THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q2 2026 (Est.) Expected 2026-06-23	Annual 2022 2022-03-31	Q4 2021 2021-12-31	Annual 2021 2021-03-31	Q4 2020 2020-12-31
Revenue	$0.00	$0.00	$0.00	$196.00K	$81.00K
Operating Income	Not available	$-15.59M	$-11.19M	$-16.42M	$-14.12M
Net Income	Not available	$-9.82M	$-5.92M	$-19.68M	$-14.03M
EPS (Diluted)	$-0.23	$-0.27	$-0.23	Not available	Not available
Total Assets	Not available	$128.62M	$114.23M	$62.46M	$30.30M
Total Liabilities	Not available	$20.35M	$3.17M	$6.80M	$4.59M
Cash & Equivalents	Not available	$30.34M	$33.01M	$50.94M	$26.55M
Free Cash Flow OCF − CapEx	Not available	Not available	Not available	Not available	Not available
Shares Outstanding	Not available	44.29M	25.79M	Not available	Not available

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.